HSP90AB1 and lung carcinoma: As shown in Table 2, thoracic perfusion of cisplatin down-regulated the Hsp90-beta level in MPE of lung cancer patients (2.01 ± 0.66 ng/mL versus 1.82 ± 0.23 ng/mL) (P < 0.001) (Fig. 1c).